









































## In Person Clinical Trials















 <p>CELL THERAPY</p>	<p><b><u>VERTEX VX-880</u></b> AGES 18-65 2 EPISODES OF SEVERE HYPOGLYCEMIA T1D AT LEAST 5 YEARS LOCATION: MA</p>	
 <p>CELL THERAPY</p>	<p><b><u>VERTEX VX-264</u></b> AGES 18-65 T1D FOR AT LEAST 5 YEARS LOCATION: MA</p>	
 <p>DEVICE</p>	<p><b><u>PRECISION II STUDY</u></b> AGES 18-75 T1D AT LEAST 3 MONTHS LOCATION: MA</p>	
 <p>DEVICE</p>	<p><b><u>TANGO</u></b> PARTICIPANTS OVER 65 MDI OR PUMP LOCATION: MA</p>	
 <p>OBSERVATIONAL</p>	<p><b><u>JOSLIN HEART AND KIDNEY</u></b> AGES 25-65    DIAGNOSED BEFORE 41 NORMAL/MODERATELY DECREASED KIDNEY FUNCTION LOCATION: MA</p>	
 <p>DEVICE</p>	<p><b><u>CIAO</u></b> AGES 18-35 or 65+ MULTIPLE DAILY INJECTIONS LOCATION: MA</p>	

 OBSERVATIONAL	<p align="center"><b><u>PROMISE</u></b>  PREGNANT WOMEN/BIOLOGICAL FATHERS  OF OFFSPRING W/ 1ST DEGREE T1D  RELATIVE  LOCATION: MA</p>	
 DRUG	<p align="center"><b><u>EFFECTS OF KETOSIS ON BRAIN FUNCTION</u></b>  AGES 18-40  T1D AT LEAST 1 YEAR WITH A1C 6.5-9%  USE OF CGM AND INSULIN PUMP  LOCATION: MA</p>	
 OBSERVATIONAL	<p align="center"><b><u>BONE HEALTH IN T1D YOUTH</u></b>  AGES 6-20  WITH T1D AND WITHOUT T1D  EARN UP TO \$300  LOCATION: MA</p>	
 DEVICE	<p align="center"><b><u>EVERSENSE</u></b>  PARTICIPANTS OVER 18  NOT CURRENTLY USING CGM  LOCATION: VT</p>	
 OBSERVATIONAL	<p align="center"><b><u>IMMUNE FUNCTION</u></b>  ALL AGES T1DS AND/OR  FAMILY MEMBERS OF T1DS  EARN \$20  LOCAL LAB</p>	
 BEHAVIORAL	<p align="center"><b><u>VERY LOW CARB DIET STUDY</u></b>  AGES 18-40  T1D AT LEAST 1 YEAR WITH A1C 6.5-9%  LOCATION: MA</p>	
 BEHAVIORAL	<p align="center"><b><u>iACT FOR EATING DISORDERS</u></b>  AGES 16-45  LIVING W/ EATING DISORDER  LOCATION: RI</p>	

 <b>DRUG</b>	<p align="center"><b><u>SUGARNSALT</u></b></p> <p align="center">AGES 18-75 T1D AT LEAST 8 YEARS eGFR between 20-60 and urine ACR of 200+.</p> <p align="center">LOCATION: MA</p>	
 <b>DEVICE</b>	<p align="center"><b><u>DIABETES STUDY IN PREGNANCY</u></b></p> <p align="center">PREGNANT WITH T1D</p> <p align="center">LOCATION: MA</p>	
 <b>DEVICE</b>	<p align="center"><b><u>AGE SENSOR VALIDATION</u></b></p> <p align="center">AGES 18+ WITH AND WITHOUT T1D EARN \$300</p> <p align="center">LOCATION: MA</p>	

**Virtual Clinical Trials**

 <b>BEHAVIORAL</b>	<p align="center"><b><u>BEAD-T1D</u></b></p> <p align="center">AGES 12-21 PUBLIC PAYER INSURANCE</p> <p align="center">VIRTUAL</p>	
 <b>BEHAVIORAL</b>	<p align="center"><b><u>TELE-MED COGNITIVE BEHAVIOR THERAPY</u></b></p> <p align="center">AGES 18-35 T1D AT LEAST 6 MONTHS WITH ANXIETY OR DEPRESSION</p> <p align="center">VIRTUAL</p>	
 <b>BEHAVIORAL</b>	<p align="center"><b><u>CGM SHARING IN OLDER ADULTS</u></b></p> <p align="center">AGES 60+ A1C 7.5-11%</p> <p align="center">VIRTUAL</p>	
 <b>PREVENTION</b>	<p align="center"><b><u>TRIALNET</u></b></p> <p align="center">DIRECT RELATIVES OF T1DS AGES 2-45</p> <p align="center">VIRTUAL OR TRIALNET CENTER</p>	

 <b>SURVEY</b>	<p align="center"><b><u>T1D EXCHANGE REGISTRY</u></b>  <b>INDIVIDUALS WITH T1D AND/OR THEIR CAREGIVERS</b></p> <p align="center">VIRTUAL</p>	
 <b>BEHAVIORAL</b>	<p align="center"><b><u>T1D BODY ACCEPTANCE PROJECT</u></b>  <b>FEMALES AGES 15-30 W/ BODY IMAGE CONCERNS AND/OR DISORGANIZED EATING EARN \$110</b></p> <p align="center">VIRTUAL/MA</p>	
 <b>DEVICE</b>	<p align="center"><b><u>EXTENDED BOLUS CLOSED LOOP</u></b>  <b>AGES 13-18  T1D AT LEAST 1 YEAR  USING CONTROL IQ</b></p> <p align="center">VIRTUAL</p>	
 <b>BEHAVIORAL</b>	<p align="center"><b><u>TRANSDISCIPLINARY CARE FOR TRANSITION</u></b>  <b>AGES 17-25 APPROACHING PEDIATRIC DISCHARGE - EARN \$180</b></p> <p align="center">VIRTUAL</p>	
 <b>BEHAVIORAL</b>	<p align="center"><b><u>ReDUcE</u></b>  <b>AGES 18-64  T1D AT LEAST 6 MONTHS  A1C&gt;7.5%</b></p> <p align="center">VIRTUAL</p>	
 <b>SURVEY</b>	<p align="center"><b><u>TIME IN TIGHT RANGE</u></b>  <b>AGES 18+</b></p> <p align="center">VIRTUAL</p>	
 <b>SURVEY</b>	<p align="center"><b><u>BC CONNELL SCHOOL OF NURSING</u></b>  <b><u>COST OF T1D</u></b>  <b>AGES 18-30 ENGLISH SPEAKING EARN \$50</b></p> <p align="center">VIRTUAL</p>	



# Newly Diagnosed Clinical Trials



DRUG

## **JAKPOT-T1D**

AGES 12-35  
T1D LESS THAN 100 DAYS, A1C <10%

LOCATION: MA



DRUG

## **T1D RELAY**

AGES 8-45  
T1D LESS THAN 100 DAYS

LOCATION: MA




DRUG

## **DIAGNODE-3**

AGES 12-28  
WITHIN 6 MONTHS OF DIAGNOSIS

LOCATION: MA



DRUG

## **FABULINUS**

AGES 12-35  
T1D LESS THAN 90 DAYS W/ 1 ANTIBODY

LOCATION: MA



# Early Stage T1D Trial



OBSERVATIONAL

## **PREDICT**

AGES 12-30  
AT LEAST 1 T1D ANTIBODY - EARN \$1500

LOCATION: CT



**Clinical Trials Connection Tool**  
**Match to a Clinical Trial in 60 Seconds**



Breakthrough T1D Greater New England  
Clinical Trial Education Volunteers  
AmandaJGilchrist@gmail.com and Kristin.Neff@gmail.com